A. Tekinalp, T. U. Kars, H. Z. Dikici, Sinan Demircioğlu, Özcan Çeneli
{"title":"血液系统恶性肿瘤的长期分析:COVID-19患者与非COVID-19患者","authors":"A. Tekinalp, T. U. Kars, H. Z. Dikici, Sinan Demircioğlu, Özcan Çeneli","doi":"10.36519/kd.2022.4182","DOIUrl":null,"url":null,"abstract":"Objective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies.\n\nMethods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn’t have COVID-19 [COVID (-)].\n\nResults: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%).\n\nConclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19.\n\nKEYWORDS\nCOVID-19, hematological malignancies, pandemic, SARS-CoV-2","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Long-Term Analysis of Hematological Malignancies: Patients with COVID-19 versus without COVID-19\",\"authors\":\"A. Tekinalp, T. U. Kars, H. Z. Dikici, Sinan Demircioğlu, Özcan Çeneli\",\"doi\":\"10.36519/kd.2022.4182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies.\\n\\nMethods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn’t have COVID-19 [COVID (-)].\\n\\nResults: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%).\\n\\nConclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19.\\n\\nKEYWORDS\\nCOVID-19, hematological malignancies, pandemic, SARS-CoV-2\",\"PeriodicalId\":44309,\"journal\":{\"name\":\"Klimik Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klimik Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36519/kd.2022.4182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klimik Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/kd.2022.4182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The Long-Term Analysis of Hematological Malignancies: Patients with COVID-19 versus without COVID-19
Objective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies.
Methods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn’t have COVID-19 [COVID (-)].
Results: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%).
Conclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19.
KEYWORDS
COVID-19, hematological malignancies, pandemic, SARS-CoV-2
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
